MSA Signed and Funding Update

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that it has signed a master services agreement ("MSA") with Gastro Health ("GH"), a leading clinical trial site network in the United States, to partner and support trial site performance with the use of the TrialSet™ suite of engagement tools, as well as to co-market each other's services.

Whilst the MSA is not immediately revenue-generating, it further validates the strength and differentiation of the Company's TrialSet™ offering in the clinical trial sector and establishes a framework for future commercial opportunities. It also enables each party access to each other's client base through opportunities to co-market. The Company is also progressing advanced late stage discussions regarding an additional clinical trial collaboration and will update the market in due course.

• Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "This MSA with Gastro Health, alongside the recent extension of our collaboration with J&J and the continued roll-out of TrialSet™ across multiple clinical trials with our CRO partners, further supports the applicability of our platform and proprietary resilience methodology across the pharmaceutical lifecycle, from clinical development through to commercial deployment. We remain focused on disciplined cost management while advancing commercial discussions and converting pipeline opportunities into revenue."

The Company has continued to reduce its monthly cash burn to an average of c. $300k as of March 2026, and expects its cash runway to extend into early April 2026. In addition, the Company is progressing discussions regarding a potential loan from certain Directors and will update the market as appropriate. The Convertible Facility provided by Alumni Capital LLC remains in place, although utilisation is currently constrained by market conditions.

The Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.